Ruthenium(II) p-cymene complex bearing 2,2 `-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response
2015
Аутори:
Kaluđerović, Goran N.Krajnović, Tamara
Momčilović, Miljana
Stošić-Grujičić, Stanislava
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Hey-Hawkins, Evamarie
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
{[}Ru(eta(6)-p-cym)Cl\{dpa(CH2)(4)COOEt\}]{[}PF6] (cym = cymene; dpa =
2,2'-dipyridylamine; complex 2) was prepared and characterized by
elemental analysis, IR and multinuclear NMR spectroscopy, as well as
ESI-MS and X-ray structural analysis. The structural analog without a
side chain {[}Ru(eta(6)-p-cym)Cl(dpa)]{[}PF6] (1) as well as 2 were
investigated in vitro against 518A2, SW480, 8505C, A253 and MCF-7 cell
lines. Complex 1 is active against all investigated tumor cell lines
while the activity of compound 2 is limited only to caspase 3 deficient
MCF-7 breast cancer cells, however, both are less active than cisplatin.
As CD4(+)Th cells are necessary to trigger all the immune effector
mechanisms required to eliminate tumor cells, besides testing the in
vitro antitumor activity of 1 and 2, the effect of ruthenium(II)
complexes on the cells of the adaptive immune system have also been
evaluated. Importantly, complex 1 applied in concentrations which were
effective against tumor cells did not affect immune cell viability, nor
did exert a general immunosuppressive effect on cytokine production.
Thus, beneficial characteristics of 1 might contribute to the overall
therapeutic properties of the complex. (C) 2015 Elsevier Inc. All rights
reserved.
Кључне речи:
Ruthenium(II); Cisplatin; Anticancer drugs; Immune cells; CytokinesИзвор:
Journal of Inorganic Biochemistry, 2015, 153, 315-321
DOI: 10.1016/j.jinorgbio.2015.09.006
ISSN: 1873-3344